Supernus Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Supernus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#343 of 15,742 sponsors by registered trial count).
Supernus Pharmaceuticals: 57 sponsored US clinical trials, 6 recruiting.
Supernus Pharmaceuticals sponsors 57 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 45 completed. 26 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sialorrhea, with 2 trials.
Top-decile sponsor footprint
Supernus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#343 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
45 of 50 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
57 total, page 1 of 2
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
NCT07141329
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
NCT07219927
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
NCT06798896
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
NCT04781140
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT05518578
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
NCT02736656
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
NCT06185985
Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
NCT06259331
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
NCT05645432
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
NCT05655520
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
NCT05619692
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
NCT05318937
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
NCT05358821
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
NCT05107128
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
NCT05059600
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
NCT05049343
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
NCT04786990
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
NCT04602624
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
NCT04476017
Therapy for Migraine Prevention in Children 6-11 Years of Age
NCT04050293
Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT04143217
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
NCT04016779
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
NCT03638466
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B
NCT03787758
A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects
NCT03844906
A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
NCT03770780
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
NCT03771586
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
NCT03665038
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
NCT03615703
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
NCT03597503
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
NCT03944785
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
NCT03247556
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
NCT03247517
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
NCT03247543
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
NCT03247530
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
NCT02942004
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
NCT02942017
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
NCT02691182
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
NCT02618434
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
NCT02633527
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
NCT02618408
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
NCT02614547
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
NCT02610868
A Study With SAGE-547 for Super-Refractory Status Epilepticus
NCT02477618
Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression
NCT02285504
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02052739
Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
NCT01994109
Open-Label, Extension Study to 810P202
NCT01416064
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01364662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 18 |
| Phase 3 | 20 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Supernus Pharmaceuticals pipeline
6 recruiting of 57 indexed (11% open); 45 completed (79%).
Phase mix: 26 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Sialorrhea (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Supernus Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 57 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Supernus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 57 trials (± recruiting share)
- Edwards Lifesciences · 57 trials · 18% recruiting
- St. Luke's-Roosevelt Hospital Center · 57 trials · 0% recruiting
- USDA Grand Forks Human Nutrition Research Center · 57 trials · 4% recruiting
- East Carolina University · 58 trials · 12% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Bastyr University · 11% recruiting · 19 trials
- Corewell Health West · 11% recruiting · 38 trials
- Ethicon · 11% recruiting · 38 trials
- Rowan University · 11% recruiting · 19 trials
Related
What to do with this Supernus Pharmaceuticals page
57 registered trials is a research-attention snapshot, not an endorsement of Supernus Pharmaceuticals or any single study.
- 6 of Supernus Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sialorrhea is the condition Supernus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sialorrhea trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Supernus Pharmaceuticals pipeline card: 57 registered trials from official public datasets.Report a data error.